Cost Benefit Analysis (CBA) or Cost Utility Analysis (CUA). Both have inherent lapses. CUA has been criticised on the basis of distant effect and CBA on the ground of ethical ground of placing monetary value on the worth of human lives. However, I think NICE is using CUA; a form of Cost-Effective analysis. There is a growing interest in CBA as an alternative to CUA in some quarters. Both provides rationale for choosing between two health interventions or drugs. The caveat is, it requires careful design in order to avoid confounders.
The problem with CUA (which uses things like DALY or QALY) is they use questionnaires such as the EQ5D which may not adequately capture many aspects affecting patients with schizophrenia (employability, stigma, relationships). Have you looked into Sen's Capabilities Approach?